Innomedica is currently running
Lipoprotein a clinical trial
Innomedica Medical Center invites you to participate in a clinical drug study. The new investigational drug is designed to lower the level of lipoprotein a (a particle that transports cholesterol in the blood) and thereby help reduce the development of major heart diseases. If you have been diagnosed with diseases of the heart and blood vessels (heart attack, stroke or peripheral artery disease), you may be a suitable candidate to participate in the study
What is lipoprotein a?
Lipoprotein a is a particle that transports cholesterol in the blood and is a known risk factor for cardiovascular disease. High levels of lipoprotein a in the blood are directly related to an increased risk of cardiovascular events such as heart attacks and aortic stenosis.
What medicine is used in this study?
The study aims to find out whether Olpasiraan (study drug) reduces the occurrence of cardiovascular complications and lowers the level of lipoprotein a. In addition, they want to know if the medicine has potential side effects.
How is the study conducted?
Around 6,000 patients are participating in this study worldwide. The study drug is administered as a subcutaneous injection approximately every three months (12-week interval). The patient is under the careful supervision of our doctors throughout the entire study period.
I would like more information.
Main criteria for eligibility to participate in the study:
- Age: 18-85 years old
- The patient has been diagnosed with cardiovascular disease (heart attack, stroke or peripheral artery disease)
- Lipoprotein a value over 200nmol/l.
During the examination, a team of doctors and nurses will closely monitor your health. All study drugs and analyzes related to the study are free for you. Participation in the study is unpaid, but you may be reimbursed for travel expenses incurred during participation.
Participation in the study is voluntary. Contacting us does not obligate you to participate in the study.
*The study has been coordinated with the Human Research Ethics Committee of the Health Development Institute and the Medicines Agency. Regulation No. 23 of the Minister of Social Affairs of 17.02.2005 “Procedure and execution of a clinical trial of a medicinal product” obliges to inform that “it is a scientific study that may involve a risk to the participant’s health”.